Abiopharma

🔍 Stevens David Todd (Executive)

Company: Figure Technology Solutions, Inc. (FIGR)

Report Date: 2026-08-14

Detailed Transactions and Holdings:

• Acquired 38,281 shares of Class A Common Stock at $4.82 per share (Direct)
  Date: 2026-08-14 | Code: M | equity_swap_involved: 0 | shares_owned_after: 424,249.00 | transaction_form_type: 4
• Sold 40,778 shares of Class A Common Stock at $31.2573 per share (Direct)
  Date: 2026-08-14 | Code: S | equity_swap_involved: 0 | shares_owned_after: 383,471.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 6,135 shares of Class A Common Stock at $32.0295 per share (Direct)
  Date: 2026-08-14 | Code: S | equity_swap_involved: 0 | shares_owned_after: 377,336.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 737 shares of Class A Common Stock at $32.9439 per share (Direct)
  Date: 2026-08-14 | Code: S | equity_swap_involved: 0 | shares_owned_after: 376,599.00 | transaction_form_type: 4 | Footnotes: F1, F4
• Sold 38,281 shares of Stock Option at $4.82 per share (Derivative)
  Date: 2026-08-14 | Code: M | Expires: 2034-11-11 | equity_swap_involved: 0 | shares_owned_after: 497,657.00 | transaction_form_type: 4 | Footnotes: F5

Footnotes:

• F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.70 to $31.68. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.70 to $32.58. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.70 to $33.18. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F5: The option vested with respect to one quarter of the underlying shares on November 11, 2025, and with respect to the remaining shares in 36 monthly installments thereafter.